Blog
RSS FeedPosted by Michael Wonder on 04 Oct 2019
Japan drug price reforms risk hurting investment: Bristol-Myers CEO
3 October 2019 - Japan’s “overly restrictive” drug pricing policies risk diverting foreign direct investment to China and other markets, ...
Posted by Michael Wonder on 18 Jun 2019
Roche wins Japan approval for personalised cancer drug Rozlytrek
18 June 2019 - Swiss drugmaker Roche’s push into personalised cancer medicines hit a milestone on Tuesday with Japanese approval ...
Posted by Michael Wonder on 21 May 2019
Extremely high drug prices should be reviewed for appropriateness
21 May 2019 - As medicine advances, a succession of highly efficacious but extremely costly therapeutic drugs have arrived on ...
Posted by Michael Wonder on 15 May 2019
Novartis gets approval to sell Kymriah in Japan for $306,000
15 May 2019 - A Japanese government panel approved on Wednesday a price of 33.5 million yen ($305,800) for Novartis’ cancer ...
Posted by Michael Wonder on 13 May 2019
Japan health ministry orders Ono Pharmaceutical to add warning to Opdivo cancer drug after death
10 May 2019 - The health ministry said Thursday that a patient taking the cancer drug Opdivo has died and ...
Posted by Michael Wonder on 09 Apr 2019
Daiichi Sankyo’s EZH1/2 dual inhibitor valemetostat (DS-3201) receives SAKIGAKE designation for treatment of patients with relapsed/refractory peripheral T-cell lymphoma from Japan MHLW
9 April 2019 - SAKIGAKE designation will provide development support and accelerated review of valemetostat, an investigational and potential first-in-class EZH1/2 ...
Posted by Michael Wonder on 26 Mar 2019
AbbVie announces first regulatory approval of Skyrizi (risankizumab) for the treatment of plaque psoriasis, generalised pustular psoriasis and erythrodermic psoriasis and psoriatic arthritis in Japan
26 March 2019 - This marks the first regulatory approval globally for SKYRIZI™ (risankizumab). ...
Posted by Michael Wonder on 23 Mar 2019
Exploring the application of cost-effectiveness evaluation in the Japanese National Health Insurance System
21 March 2019 - Japan's Central Social Insurance Medical Council (“Chuikyo”) began in 2012 to examine how cost-effectiveness evaluation might ...
Posted by Michael Wonder on 21 Feb 2019
Japan approves two gene treatments in bid to catch up
21 February 2019 - Potential revolutionary treatments have exorbitant price tags. ...
Posted by Michael Wonder on 19 Feb 2019
As medical costs mount, Japan to weigh cost-effectiveness in setting drug prices
18 February 2019 - Japanese doctor Yasushi Goto remembers prescribing the cancer drug Opdivo to an octogenarian and wondering whether ...
Posted by Michael Wonder on 12 Aug 2018
MAESTrO Database on exhibit at ISPOR Asia-Pacific Conference
12 August 2018 - Exciting new features to be launched at the conference. ...
Posted by Michael Wonder on 18 Jul 2018
EU and Japan reinforce their collaboration on inspections of medicine manufacturers
18 July 2018 - Update of 2004 mutual recognition agreement extends scope to sterile products, active pharmaceutical ingredients and biologicals ...
Posted by Michael Wonder on 17 May 2018
FDA faster than global peers at approving new drugs
16 May 2018 - A report from the Centre for Innovation in Regulatory Science released this month finds that the ...
Posted by Michael Wonder on 12 Apr 2018
Ohara cuts price of generic drug for leukaemia
11 April 2018 - Ohara Pharmaceutical Co. has reduced the price of its generic drug for leukaemia to about half ...
Posted by Michael Wonder on 06 Mar 2018
Government to cut price of Opdivo by over 20%
5 March 2018 - Japan’s health ministry said Monday that the government-set price of cancer drug Opdivo will be reduced ...